Peptides and NAD+: where each stands with the FDA
Whether a pharmacy may compound a substance for your prescription is decided ingredient by ingredient, and for several peptides it changed in 2026. Each compound's page quotes the FDA's current words and the day we read them.
| Compound | Lowest monthly price | Sellers | Sold as | FDA standing |
|---|---|---|---|---|
| NAD+Coenzyme | $23.14/moat TomorrowsRx | 421 | injection, nasal spray, cream | FDA Category 1: under review, compounding tolerated |
| SermorelinGHRH analog | ≈ $69/moat T·TIME | 371 | injection, tablet, troche | Compoundable as an approved drug's ingredient |
| GlutathioneAntioxidant | $39/moat Gatlan | 259 | injection, nasal spray, troche | FDA Category 1: under review, compounding tolerated |
| PT-141Melanocortin agonist | $65/moat Everlife | 124 | injection, nasal spray, troche | FDA-approved brandCompoundable as an approved drug's ingredient |
| GHK-CuPeptide | $55/moat Everlife | 97 | cream, injection, tablet | Depends on the route |
| BPC-157Peptide | $109/moat Enhanced | 91 | injection, capsule, tablet | Allowed under HHS's Oct 2026 draft policy |
| MOTS-cPeptide | $109/moat Enhanced | 76 | injection | Allowed under HHS's Oct 2026 draft policy |
| TB-500Peptide | $99/moat Ascend Vitality | 59 | injection | Allowed under HHS's Oct 2026 draft policy |
| EpitalonPeptide | $58.33/moat EllieMD | 48 | injection | Allowed under HHS's Oct 2026 draft policy |
| TesamorelinGHRH analog | ≈ $123/moat Balanced Hormone Health | 42 | injection | FDA-approved brandA biologic: not for compounding |
| SemaxPeptide | $79/moat PepScribe | 39 | nasal spray, injection | Allowed under HHS's Oct 2026 draft policy |
| KPVPeptide | $90at Padgett Medical Center | 23 | capsule, cream, injection | Allowed under HHS's Oct 2026 draft policy |
| CJC-1295GHRH analog | $150/moat Live Vital | 22 | injection | No route for pharmacies to compound it |
| Thymosin alpha-1Peptide | $199/moat Biotech Lifestyle | 17 | injection | No route for pharmacies to compound it |
| DSIPPeptide | $161.10/moat FormBlends | 17 | injection, nasal spray, capsule | No route for pharmacies to compound it |
| SelankPeptide | $152.10/moat FormBlends | 10 | nasal spray, injection | No route for pharmacies to compound it |
| SS-31Peptide | $185/moat Try Nova | 10 | injection | FDA-approved brandCompoundable as an approved drug's ingredient |
| Kisspeptin-10Peptide | $155/moat BRAVO1 Wellness | 8 | injection | FDA Category 2: significant safety risks |
| IGF-1 LR3Growth factor | $239/moat Peps RX | 8 | injection | A biologic: not for compounding |
| AOD-9604Peptide | $229/moat Pepti | 5 | injection | No route for pharmacies to compound it |
| DihexaPeptide analog | ≈ $164/moat EllieMD | 5 | capsule, injection | No route for pharmacies to compound it |
| VIP peptidePeptide | $159/moat Joi + Blokes | 5 | nasal spray | FDA Category 1: under review, compounding tolerated |
| LL-37Peptide | $179.10/moat FormBlends | 4 | injection | No route for pharmacies to compound it |
| ARA-290Peptide | $219/moat Pepti | 4 | injection | FDA Category 3: nominated without support |
| IpamorelinGH secretagogue | $239/moat Pepti | 3 | injection | No route for pharmacies to compound it |
Which compounds are in which FDA category
- Compoundable as an approved drug's ingredient
- Sermorelin, PT-141 and SS-31
- FDA Category 1: under review, compounding tolerated
- NAD+, Glutathione and VIP peptide
- Depends on the route
- GHK-Cu
- FDA Category 2: significant safety risks
- Kisspeptin-10
- FDA Category 3: nominated without support
- ARA-290
- A biologic: not for compounding
- Tesamorelin and IGF-1 LR3
- No route for pharmacies to compound it
- CJC-1295, Thymosin alpha-1, DSIP, Selank, AOD-9604, Dihexa, LL-37 and Ipamorelin
Each compound's page quotes the FDA or HHS record behind its standing, with the day we read it.
How a pharmacy may compound a peptide at all
A pharmacy that compounds for one patient's prescription (a 503A pharmacy) may use an ingredient only if it is part of an FDA-approved drug, has a USP or NF monograph, or is on the FDA's short list of bulk substances it has accepted. For substances still under review, the FDA keeps interim lists: it tolerates compounding with Category 1 substances while it evaluates them, and treats Category 2 as raising significant safety risks.
On 30 October 2026 the Department of Health and Human Services published a draft policy saying it does not intend to act against 503A pharmacies compounding BPC-157, MOTS-c, TB-500, Epitalon, Semax and KPV, each only in the form and routes it names and under ten conditions, including a single ingredient per product. It does not cover outsourcing facilities (503B), and none of the six is on the bulks list.
For CJC-1295, Thymosin alpha-1, DSIP, Selank, AOD-9604, Dihexa, LL-37 and Ipamorelin, no list or policy gives a pharmacy a route to compound them today.
Outsourcing facilities (503B) follow separate lists, and a biological product such as tesamorelin cannot be compounded under either section.